{
    "nct_id": "NCT04256421",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)\n* No prior systemic treatment for ES-SCLC\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\n* Adequate hematologic and end-organ function\n* Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic or actively progressing central nervous system (CNS) metastases\n* Malignancies other than small cell lung cancer (SCLC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Positive test result for human immunodeficiency virus (HIV)\n* Active hepatitis B or hepatitis C\n* Severe infection at the time of randomization\n* Treatment with any other investigational agent within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4), anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to randomization",
    "miscellaneous_criteria": ""
}